Kornimate/medical-research-clean huggingface dataset:
enhanced care coordination for head and neck cancer survivors

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to evaluate the effect of a multidimensional symptom management intervention on decreasing symptom burden and thus reducing hospital utilization in patients undergoing radiation with or without chemotherapy for head and neck cancer.

the purpose of this study is to evaluate the effect of a multidimensional symptom assessment intervention on identifying symptoms and alerting care team of changes, and thus reducing hospital utilization, in patients undergoing radiation with or without chemotherapy for head and neck cancer. this is a pilot study. this project is being conducted to 1) examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation, 2) determine the hospital admission rates of this patient population before, during and post treatment, 3) compare the admission rates of this patient population to historical controls and 4) to examine overall patient compliance.

Eligibility criteria:
inclusion criteria: * age 18 and older * diagnosed with primary, head and neck cancer of the paranasal sinuses, nasal cavity, oral cavity, tongue, salivary glands, larynx, and pharynx (including the nasopharynx, oropharynx, and hypopharynx) * will include squamous cell carcinoma found in lymph nodes as a result of unknown primary location. * prior to the initiation of radiation treatment for qualifying diagnosis * treatment occurring at hillman cancer center exclusion criteria: * prior radiation treatment of squamous cell carcinoma of the locations listed in inclusion criteria.
needle length in obese insulin-using diabetic subjects

Conditions: Diabetes Mellitus

Summary: for the administration of insulin, different needles are available with a length from 5 to 12.7mm. insulin injections with a needle of 8 mm is injected in a lifted skinfold, a 5 mm needle can by used without lifting a skinfold (1). in the netherlands obese people (bmi ≥ 30) are usually advised to use an 8mm or even longer needle (1). increased bmi and the thickness of the subcutaneous tissue slow insulin absorption (2, 3, 4), possibly related to reduced subcutaneous blood flow. furthermore, the capillaries are located just under the skin and between the fat and muscle layer. this could possibly determine the absorbing speed (2). it is not know if the administration of insulin with a 5mm needle by obese people has a different influence on the hba1c compared to longer needles. the hypothesis of this study is that for the purpose of insulin injections, a 5 mm needle can be used without negative effects on metabolic parameters in patients with diabetes mellitus (dm) and a body mass index (bmi) ≥ 30.


Eligibility criteria:
inclusion criteria: * male and female adult patients diagnosed with type 1 and type 2 diabetes mellitus, treated with insulin injections for at least one year and: * using an insulin pen * a bmi \> 30 kg/m2 * a skinfold thickness of \>10 mm at the injection sites * stable glycaemic control, with hba1c between 6 and 10% * capable of reading the written information * prepared to, and capable of signing an informed consent exclusion criteria: * patients who: * change their own insulin dosage and are not prepared to keep a record of these changes * have hypoglycaemia unawareness * are pregnant or wish to become pregnant * have a bmi \< 30 kg/m2 * have a skinfold thickness \<10mm * have skin problems including lipodystrophy
dural arteriovenous fistulas research at china ini

Conditions: Fistula

Summary: dural arteriovenous fistula (davf) refers to abnormal connections between meningeal arteries and dural venous sinuses and/or subarachnoid veins. davf accounts for approximately 10% to 15% of intracranial vascular malformations. with advancements in imaging technology, increased awareness among physicians, and an aging population, the incidence of davf appears to be on the rise. some literature even suggests it may surpass the occurrence of arteriovenous malformations. several large-scale retrospective studies have been conducted internationally, involving over 1,000 cases, but some of their findings differ from what is commonly understood. currently, there is a lack of large-sample single-center studies on davf, highlighting the urgent need for such research.

title：dural arteriovenous fistulas research at china ini. purpose：the incidence of davf is low. by collecting clinical data, we aim to establish a comprehensive database and biobank. this will help us elucidate the potential pathogenesis, vascular architecture, biological markers, and treatment outcomes of davfs. furthermore, this study aims to address current controversies (such as treatment strategies for davf with pial arterial supply), unresolved issues (such as the optimal treatment and prognosis of infantile type davf), and further explore possible mechanisms of davf development.

Eligibility criteria:
inclusion criteria: * adult patients with davfs who were admitted to xuanwu hospital. exclusion criteria: * non-davf lesions confirmed by dsa.
efficacy and safety of dasiglucagon for treatment of post-bariatric hypoglycemia in roux-en-y gastric bypass (rygb) operated adults

Conditions: Hypoglycemia; Glucose Metabolism Disorders

Summary: the objective of the trial is to assess the effect of single subcutaneous doses of dasiglucagon versus placebo on post-prandial plasma glucose nadir following a mixed meal test in roux-en-y gastric bypass (rygb) subjects


Eligibility criteria:
inclusion criteria: * previously undergone roux-en-y gastric bypass (rygb) surgery at least 6 months prior to screening * previous diagnosis of post-bariatric hypoglycemia (pbh), requiring intake of oral carbohydrates. * body mass index (bmi) ≤ 40 kg/m2 * fasting plasma glucose between 72-106 mg/dl (4.0-6.0 mmol/l) exclusion criteria: * history of hypersensitivity reactions to glucagon or dasiglucagon or any of the excipients * history of insulinoma, pheochromocytoma, men 2a, men 2b, neurofibromatosis, or von hippel-lindau disease. * estimated glomerular filtration rate (egfr) \< 30 ml/min/1.73 m2 or end-stage renal disease at screening * hepatic disease, including serum alanine aminotransferase or aspartate aminotransferase ≥ 2.5 times the upper limit of normal (uln) * active malignancy, except for basal or squamous cell skin cancers * history of a cerebrovascular accident within 6 months prior to screening * history of myocardial infarction, unstable angina, or revascularization within 6 months prior to screening. * congestive heart failure, new york heart association class iii or iv * concurrent administration of β-blocker therapy * clinically significant ecg abnormalities at screening
cryptoart study: decreasing mortality associated with initiation of antiretroviral therapy in sub-saharan africa

Conditions: Cryptococcal Meningitis

Summary: the study will determine if the initiation of a 'screen and treat' program for cryptococcal disease among hiv positive individuals decreases morbidity and mortality among individuals with cd4 count \< 100 cells/mm3. the study will screen individuals who are asymptomatic for cm and are either art naïve or art experienced with cd4 count \< 100 cells/mm3. the introduction of an cheap, easy to use point of care diagnostic test the lateral flow assay will facilitate rapid diagnosis of cryptococcal disease in resource limited settings. the investigators will determine the efficacy of the lateral flow assay in identifying latent and asymptomatic cryptococcal disease. the investigators will determine the efficacy of the test in detecting disease in readily available body fluids such as urine and whole blood obtained via finger-stick method. the investigators will also determine the cost effectiveness of a screen and treat approach for cryptococcal disease in zimbabwe. the investigators also wish to understand why some individuals with low cd4 counts reactivate cryptococcal disease and screen positive for cryptococcal antigen (crag) while others with similar levels of immunocompromised do not.


Eligibility criteria:
inclusion criteria: * documented hiv positive test by standard national algorithm * cd4 count ≤100 cells/mm3 * age \> 18 years * residence within 50 km of harare * able to provide written informed consent exclusion criteria: * presence of clinical symptoms suggestive of meningitis. * recent history of cm within 2 weeks of enrollment, i.e., participants within the induction phase of therapy. * individuals with severe hepatic injury, jaundice, alanine transferase (alt) \>5x upper limit of normal * individuals with renal failure, defined by an estimated glomerular filtration rate (egfr) ≤30 ml/min (using mdrd (modification of diet in renal disease) equation) * currently known to be pregnant * a negative urine pregnancy test is required for study entry for women with childbearing potential. * the use of contraception will be recommended to women with childbearing potential while on high dose fluconazole therapy. referral to family planning services will be given as necessary. * previous allergy or other reaction to amphotericin b and/or fluconazole * currently enrolled in another clinical trial/study

Keywords: hiv cryptococcus lateral flow assay sub-saharan africa screening treatment cryptococcal meningitis
trial of zesteem (estradiol) in healing of split thickness skin graft donor sites

Conditions: Burn; Trauma; Varicose Ulcer

Summary: this trial will assess the effects of zesteem (estradiol) on the healing of split thickness skin graft donor sites in patients aged 18-85 years.


Eligibility criteria:
inclusion criteria: * patients aged 18-85 years who have provided written informed consent. * patients requiring skin grafting due to burns, trauma or chronic venous ulcers, with a donor site expected to be between 20 and 200 cm2 on a non-articulated area. * female patients of child bearing potential who are using method(s) of contraception acceptable to the investigator and agree to do so from at least the screening visit until one month after administration of the final study dose. exclusion criteria: * patients with burns involving more than 15% of their total body area. * patients with sepsis, haemodynamic instability requiring pressor support or positive blood microbiology cultures within 48h of surgery. * patients with inhalation injury requiring artificial respiratory assistance. * patients requiring skin grafts following removal of suspicious skin lesions. * patients who have received treatment with systemic steroids during the 30 days prior to surgery. * patients who have received immunosuppressive drugs, radiation or chemotherapy during the three months prior to surgery. * patients with a history of malignancy in the previous three years. * patients with uncontrolled diabetes or diabetic ulcers. * patients with diseases or conditions that could, in the opinion of the investigator, interfere with the assessment of safety, tolerability or efficacy. * patients who have previously had skin grafts harvested from the area to be studied. * patients with a skin disorder that is chronic or currently active and which the investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial. * patients with a history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial. * patients who are taking, or have taken, any investigational drugs within 3 months prior to the screening visit. * patients undergoing investigations or changes in management for an existing medical condition. * patients who are or who become pregnant up to and including day 0 or who are lactating. * in the opinion of the investigator, a patient who is not likely to complete the trial for whatever reason.
developing a culturally adapted intervention for latino youth transitioning to adulthood

Conditions: Autism Spectrum Disorder

Summary: the purpose of this study is to evaluate the acceptability, feasibility (e.g., satisfaction, completion rate, barriers to recruitment, treatment fidelity) of the culturally refined launching! to adulthood (¡iniciando! la adultez) program, to test for a preliminary signal of effect between baseline and post-treatment for the launching! to adulthood (¡iniciando! la adultez) program and to identify preliminary neural mechanisms of action, including biomarkers of brain structure and connectivity, in terms of treatment response for 15 latino young adults participating in the ¡iniciando! therapy program.

the launching! to adulthood (¡iniciando! la adultez) program uses a culturally sensitive therapy program that was translated into spanish to help latino young adults with autism spectrum disorder (asd) who are transitioning to adulthood (18-25 years old) and their parents. the program aims to make the transition to adulthood easier for young adults and their families, and it includes specific cultural values of latino young adults and their family members. the ¡iniciando! la adultez program helps autistic young adults manage mental health needs like depression and anxiety and also addresses several areas impacting transition, including mental health barriers, executive functioning, and motivation. the ¡iniciando! program also helps parents manage their own needs and addresses several areas, including psychoeducation and mental health.

Eligibility criteria:
inclusion criteria: * confirmed case of asd * a score of \>14 on the social communication questionnaire-lifetime (scq-l110) completed with the mother or father * meet dsm-5 criteria for asd based on a diagnostic and statistical manual of mental disorders (dsm)-5 asd symptom checklist * previous diagnosis of asd from a licensed mental health or medical professional * speak english * have a parent willing to participate (treatment group only) * score \>85 on verbal intelligence quotient (iq) on the kaufman brief intelligence test (kbit-2) exclusion criteria: * history of a psychotic disorder or current psychotic symptoms * suicidal ideation with intent or plan * current alcohol or other substance use disorder rated severe * concurrent enrollment in another clinical trial for autism spectrum disorder * expression of unwillingness to complete study procedures * for fmri, unable to undergo fmri scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips, or other implanted metal parts) or claustrophobic to the scanner.
squish-covid: a pilot study

Conditions: Sepsis; COVID-19

Summary: this is a single-site prospective study to evaluate the diagnostic performance of the investigational septiscan system for patients presenting to the emergency department with signs or suspicion of covid-19 or other infectious respiratory diseases.


Eligibility criteria:
inclusion criteria: subjects meeting the following criteria may be eligible for participation in the study: 1. ≥ 18 years old or older 2. the first vital sign (any one of: blood pressure, temperature, pulse or respiratory rate) has been recorded in the medical record 3. a complete blood count has been ordered for which a blood sample has been collected within 4.5 hours since the first vital sign was recorded 4. signs or suspicion of a respiratory infection, defined as: 1. subject designated for evaluation in the ed respiratory or pulmonary pod or similar location. or 2. an order placed for a respiratory viral panel. or 3. an order placed for a sars-cov-2 test. or 4. a subject self-reported as having tested positive for the sars-cov-2 test within the previous 7 days and returning with a related complaint. exclusion criteria: subjects are excluded from study participation if they meet any of the following criteria: a. blood sample volume is \< 300 ul; insufficient quantity for septiscan testing.

Keywords: sepsis covid
pde-4 inhibitor roflumilast and polycystic ovary syndrome

Conditions: PCOS; Obesity

Summary: the purpose of this study was to determine whether combined treatment with phosphodiesterase-4 (pde-4) inhibitor roflumilast and metformin is more effective than metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (pcos) who had been previously poor responders regarding weight reduction on metformin monotherapy. the investigators anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with metformin.


Eligibility criteria:
inclusion criteria: * 18 years old to menopause * polycystic ovary syndrome (nichd criteria) * bmi of 30 kg/m² or higher exclusion criteria: * depression * type 1 or type 2 diabetes mellitus * history of carcinoma * cushing's syndrome or congenital (non-classic) adrenal hyperplasia * significant cardiovascular, kidney or hepatic disease * the use of medications other than metformin known or suspected to affect reproductive or metabolic functions * the use of statins, within 90 days prior to study entry

Keywords: pcos pde-4 inhibitor roflumilast metformin obesity
maintenance treatment for ovarian carcinoma in remission by an antiangiogenic treatment strategy

Conditions: Ovarian Carcinoma

Summary: preclinical studies showed that metronomic chemotherapy can induce tumor regression secondary to apoptosis of the tumor blood vessels. this effect was increased by combining metronomic chemotherapy with anti-angiogenic drugs. metronomic chemotherapy has already proved clinical effects too, especially on patients with breast or prostate carcinoma. this study is aimed to test the efficacy of an experimental metronomic chemotherapy regimen in a cohort of patients with ovarian cancer. patients will receive the proposed regimen as maintenance treatment following response induction by the conventional maximal tolerated dose (mtd) regimen of carboplatin and paclitaxel. our regimen will include cytophosphan combined with two agents which are expected to act as indirect angiogenic inhibitors: (a) celecoxib, as a selective cox-2 inhibitor and (b) low-dose methotrexate, as successfully practiced for suppressing the inflammatory manifestations of rheumatoid arthritis. all components of our regimen will be administered orally and continuously for one year based on the hypothesis that its anti-angiogenic properties will be able to suppress the recovery of residual disease, thus extending the time to progression (ttp), and possibly the overall survival as well.


Eligibility criteria:
inclusion criteria: 1. histologic proof of papillary-serous ovarian cancer or 1ary peritoneal carcinomatosis. 2. histological grade iii. 3. original disease in stage iii. 4. ecog performance status: 0-2. 5. age: 20-80 years. 6. previous chemotherapy with paclitaxel and carboplatin (only). 7. previous cyto-reductive surgery. 8. clinical complete response (both physically and by imaging). 9. ca 125 should be either normalized (in at least 50 patients) or while still in decreasing values at monthly measurements. 10. cbc at normal values or with any toxicity at a grade limited to i by ncic-ctc. 11. liver and renal functions \< 1.5 upper normal limits (unl) by sma. 12. the patient's signature on the informed consent. exclusion criteria: 1. mucinous type ovarian carcinoma. 2. histological grade i-ii. 3. current continuous treatment by steroids or by nsaids, or by anti-coagulants for "non protocol" reasons. 4. previous history of active peptic ulcer. 5. current participation in any other treatment study.

Keywords: ovary carcinoma maintenance metronomic chemotherapy time to progression overall survival
changes in renal function and body composition in pulmonary hypertension

Conditions: Pulmonary Hypertension; Renal Function Abnormal

Summary: changes in renal function and body composition in patients with pulmonary hypertension

this prospective single-center study is designed to analyze changes in renal function and body composition in patients with suspected or pre-diagnosed pulmonary hypertension at pulmonary hypertension outpatient clinic, university hospital giessen and marburg, campus giessen.

Eligibility criteria:
inclusion criteria: * subjects older than 18 years at pulmonary hypertension outpatient clinic * subjects who signed informed consent forms exclusion criteria: * patients refusing to participate or withdraw consent during follow-up
therapeutic rainforest study in generating positive energy among undergraduate students

Conditions: Stress; Anxiety

Summary: this study looked into how therapeutic forest walking will impact the well-being of undergraduate students at the national university of singapore. a three-arm randomized control trial on 108 participants is being planned for this study. the primary aim of this study is to assess the feasibility and primary effect of the therapeutic rainforest walking in generating positive energy among undergraduate students project in enhancing the quality of life, physical, mental, and psycho-social well-being among university students.


Eligibility criteria:
inclusion criteria: * current nus undergraduate students * no self-reported physical mobility issue * no self-reported existing mental health conditions * enjoys nature exclusion criteria: -

Keywords: mental health; well-being; stress;
pith moromo 2: cohort to study health consequences of food and nutrition insecurity during pregnancy and lactation

Conditions: Food Insecurity; Nutrition; Maternal and Child Health; HIV

Summary: in this study, the investigators conducted research among hiv-infected and -uninfected pregnant and lactating women to understand the potential role and importance of food insecurity on participant physical and psychosocial health and nutrition.

the central hypothesis of this study was that food and nutrition insecurity are detrimental to the health of hiv+ pregnant women and their infants via nutritional, disease, and psychosocial pathways. in the first phase, the investigators collected descriptive data to describe and assess food and nutrition insecurity and the associated modifiable determinants among hiv+ pregnant and lactating women in kenya. in the second phase, the investigators collected longitudinal cohort data from women who were recruited during pregnancy and have been followed throughout the infant's first year of life.

Eligibility criteria:
inclusion criteria: * women \>18 years of age with infants * infants born to pregnant women enrolled in the cohort study * hiv-infected pregnant women \>18 years of age and ≤30 weeks gestation * hiv-uninfected pregnant women \>18 years of age and ≤30 weeks gestation exclusion criteria: * individuals \<18 years of age that are not infants born to women enrolled in the cohort study